Molecular Templates (MTEM) PT Raised to $20 at Laidlaw, Following Report of First Patient Dosing in Phase I Study of TAK-169 in Relapsed/Refractory Multiple Myeloma
Tweet Send to a Friend
Laidlaw analyst Yale Jen raised ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
